COR170
COR170 (11u) is a selective CB2 inverse-agonist which is a 4-quinolone-3-carboxylic acid derivative with a Ki value of 3.8 nM for CB2 receptor. COR170 can be used for the research of inflammation and neuroprotection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 1048039-15-1
- Formel: C31H36N2O2
- Molecular Weight:468.63
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-15443
AM251CB1 Receptor Antagonist -
HY-14136
Rimonabant -
HY-10871
OtenabantCannabinoid Receptor Antagonist -
HY-14167
GW842166XCannabinoid Receptor Agonist -
HY-13288
Org 27569Cannabinoid Receptor Modulator -
HY-103325
JTE-907Cannabinoid CB2 Receptor Inverse Agonist -
HY-14791A
(±)-IbipinabantCannabinoid Receptor Antagonist -
HY-10013
TaranabantCB1 Receptor Invert Agonist -
HY-15420
BML-190Cannabinoid Receptor Agonist -
HY-14137
Rimonabant HydrochlorideCB1 Antagonist -
HY-N2327
OleamideEndogenous Metabolite -
HY-13505
AM281CB1 Antagonist
Biologische Aktivität
Beschreibung
In Vitro
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mice with formalin (1.25%, 30 μL) injections[3]
-
Dosage:1.5, 3 and 6 mg/kg
-
Administration:Intraperitoneal injection; 1.5, 3 and 6 mg/kg for once
-
Result:Reduced the late phase nociceptive behaviour induced by formalin with a 6 mg/kg dose and 10 min before formalin and abolished the analgesic effect from GW405833 which is a CB2 receptor partial agonist.
Chemical Information
-
CAS. Nr. 1048039-15-1
-
Molecular Weight 468.63
-
Formel C31H36N2O2
-
SMILES
O=C(C1=CN(CCCCC)C2=CC=C(C3=CC=CC=C3)C=C2C1=O)NC45C[C@H](C6)C[C@H](C[C@H]6C5)C4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
[1]. Contartese A, et al. A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury. Pharmacol Res. 2012 Dec;66(6):555-63. [Content Brief]
[2]. Pasquini S, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo. J Med Chem. 2008 Aug 28;51(16): [Content Brief]
[3]. Cascio MG, et al. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists. Pharmacol Res. 2010 Apr;61(4):349-54. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
COR170 Related Classifications
HY-103331 Related Classifications
Powered by Bioz